TY - JOUR
T1 - Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI)
T2 - A prospective, multicentre, comparative effectiveness study
AU - Wiegers, Eveline Janine Anna
AU - Lingsma, Hester Floor
AU - Huijben, Jilske Antonia
AU - Cooper, David James
AU - Citerio, Giuseppe
AU - Frisvold, Shirin
AU - Helbok, Raimund
AU - Maas, Andrew Ian Ramsay
AU - Menon, David Krishna
AU - Moore, Elizabeth Madeleine
AU - Stocchetti, Nino
AU - Dippel, Diederik Willem
AU - Steyerberg, Ewout Willem
AU - van der Jagt, Mathieu
AU - Brooker, Joanne
AU - Bragge, Peter
AU - Rosenfeld, Jeffrey
AU - Cooper, Jamie D.
AU - Beer, Ronny
AU - Schoechl, Herbert
AU - Rusnák, Martin
AU - Schwendenwein, Elisabeth
AU - Antoni, Anna
AU - De Keyser, Véronique
AU - Menovsky, Tomas
AU - Van Praag, Dominique
AU - Maas, Andrew I.R.
AU - Van der Steen, Gregory
AU - Parizel, Paul M.
AU - Vande Vyvere, Thijs
AU - Depreitere, Bart
AU - Van Hecke, Wim
AU - Verheyden, Jan
AU - Misset, Benoit
AU - Ledoux, Didier
AU - Laureys, Steven
AU - Ghuysen, Alexandre
AU - Maréchal, Hugues
AU - Dulière, Guy Loup
AU - Gao, Guoyi
AU - Jiang, Ji yao
AU - Kondziella, Daniel
AU - Fabricius, Martin
AU - Schou, Rico Frederik
AU - Blaabjerg, Morten
AU - Rosenlund, Christina
AU - Piippo-Karjalainen, Anna
AU - Raj, Rahul
AU - Pirinen, Matti
AU - Ylén, Peter
AU - CENTER-TBI and OzENTER-TBI Collaboration Groups
AU - CENTER-TBI
N1 - Funding Information:
This research was funded by the European Commission 7th Framework program (grant number 602150), the Australian National Health and Medical Research Council (NHMRC; grant number 1074181), and the Transport Accident Commission Victoria Australia (grant ISCRR N-14-129). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), OneMind (USA), Integra LifeSciences (USA), and Neurotrauma Sciences (USA). We thank all patients for their participation in the CENTER-TBI study and the OzENTER-TBI study. We also thank all principal investigators and researchers for collecting ICU data and for sharing their valuable expertise, and the InTBIR funders and investigators for their collaboration and support.
PY - 2021/8
Y1 - 2021/8
N2 - Background: Fluid therapy—the administration of fluids to maintain adequate organ tissue perfusion and oxygenation—is essential in patients admitted to the intensive care unit (ICU) with traumatic brain injury. We aimed to quantify the variability in fluid management policies in patients with traumatic brain injury and to study the effect of this variability on patients' outcomes. Methods: We did a prospective, multicentre, comparative effectiveness study of two observational cohorts: CENTER-TBI in Europe and OzENTER-TBI in Australia. Patients from 55 hospitals in 18 countries, aged 16 years or older with traumatic brain injury requiring a head CT, and admitted to the ICU were included in this analysis. We extracted data on demographics, injury, and clinical and treatment characteristics, and calculated the mean daily fluid balance (difference between fluid input and loss) and mean daily fluid input during ICU stay per patient. We analysed the association of fluid balance and input with ICU mortality and functional outcome at 6 months, measured by the Glasgow Outcome Scale Extended (GOSE). Patient-level analyses relied on adjustment for key characteristics per patient, whereas centre-level analyses used the centre as the instrumental variable. Findings: 2125 patients enrolled in CENTER-TBI and OzENTER-TBI between Dec 19, 2014, and Dec 17, 2017, were eligible for inclusion in this analysis. The median age was 50 years (IQR 31 to 66) and 1566 (74%) of patients were male. The median of the mean daily fluid input ranged from 1·48 L (IQR 1·12 to 2·09) to 4·23 L (3·78 to 4·94) across centres. The median of the mean daily fluid balance ranged from −0·85 L (IQR −1·51 to −0·49) to 1·13 L (0·99 to 1·37) across centres. In patient-level analyses, a mean positive daily fluid balance was associated with higher ICU mortality (odds ratio [OR] 1·10 [95% CI 1·07 to 1·12] per 0·1 L increase) and worse functional outcome (1·04 [1·02 to 1·05] per 0·1 L increase); higher mean daily fluid input was also associated with higher ICU mortality (1·05 [1·03 to 1·06] per 0·1 L increase) and worse functional outcome (1·04 [1·03 to 1·04] per 1-point decrease of the GOSE per 0·1 L increase). Centre-level analyses showed similar associations of higher fluid balance with ICU mortality (OR 1·17 [95% CI 1·05 to 1·29]) and worse functional outcome (1·07 [1·02 to 1·13]), but higher fluid input was not associated with ICU mortality (OR 0·95 [0·90 to 1·00]) or worse functional outcome (1·01 [0·98 to 1·03]). Interpretation: In critically ill patients with traumatic brain injury, there is significant variability in fluid management, with more positive fluid balances being associated with worse outcomes. These results, when added to previous evidence, suggest that aiming for neutral fluid balances, indicating a state of normovolaemia, contributes to improved outcome. Funding: European Commission 7th Framework program and the Australian Health and Medical Research Council.
AB - Background: Fluid therapy—the administration of fluids to maintain adequate organ tissue perfusion and oxygenation—is essential in patients admitted to the intensive care unit (ICU) with traumatic brain injury. We aimed to quantify the variability in fluid management policies in patients with traumatic brain injury and to study the effect of this variability on patients' outcomes. Methods: We did a prospective, multicentre, comparative effectiveness study of two observational cohorts: CENTER-TBI in Europe and OzENTER-TBI in Australia. Patients from 55 hospitals in 18 countries, aged 16 years or older with traumatic brain injury requiring a head CT, and admitted to the ICU were included in this analysis. We extracted data on demographics, injury, and clinical and treatment characteristics, and calculated the mean daily fluid balance (difference between fluid input and loss) and mean daily fluid input during ICU stay per patient. We analysed the association of fluid balance and input with ICU mortality and functional outcome at 6 months, measured by the Glasgow Outcome Scale Extended (GOSE). Patient-level analyses relied on adjustment for key characteristics per patient, whereas centre-level analyses used the centre as the instrumental variable. Findings: 2125 patients enrolled in CENTER-TBI and OzENTER-TBI between Dec 19, 2014, and Dec 17, 2017, were eligible for inclusion in this analysis. The median age was 50 years (IQR 31 to 66) and 1566 (74%) of patients were male. The median of the mean daily fluid input ranged from 1·48 L (IQR 1·12 to 2·09) to 4·23 L (3·78 to 4·94) across centres. The median of the mean daily fluid balance ranged from −0·85 L (IQR −1·51 to −0·49) to 1·13 L (0·99 to 1·37) across centres. In patient-level analyses, a mean positive daily fluid balance was associated with higher ICU mortality (odds ratio [OR] 1·10 [95% CI 1·07 to 1·12] per 0·1 L increase) and worse functional outcome (1·04 [1·02 to 1·05] per 0·1 L increase); higher mean daily fluid input was also associated with higher ICU mortality (1·05 [1·03 to 1·06] per 0·1 L increase) and worse functional outcome (1·04 [1·03 to 1·04] per 1-point decrease of the GOSE per 0·1 L increase). Centre-level analyses showed similar associations of higher fluid balance with ICU mortality (OR 1·17 [95% CI 1·05 to 1·29]) and worse functional outcome (1·07 [1·02 to 1·13]), but higher fluid input was not associated with ICU mortality (OR 0·95 [0·90 to 1·00]) or worse functional outcome (1·01 [0·98 to 1·03]). Interpretation: In critically ill patients with traumatic brain injury, there is significant variability in fluid management, with more positive fluid balances being associated with worse outcomes. These results, when added to previous evidence, suggest that aiming for neutral fluid balances, indicating a state of normovolaemia, contributes to improved outcome. Funding: European Commission 7th Framework program and the Australian Health and Medical Research Council.
UR - http://www.scopus.com/inward/record.url?scp=85110576459&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(21)00162-9
DO - 10.1016/S1474-4422(21)00162-9
M3 - Article
C2 - 34302787
AN - SCOPUS:85110576459
SN - 1474-4422
VL - 20
SP - 627
EP - 638
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 8
ER -